RxDoctor Payments Data

Jennifer Sims, NP

Family · Ardmore, OKNPI 1730720723

Payments from drug & device makers

$3,035in general payments, 2019–2025

Across 169 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$582
  • Fresenius USA Marketing, Inc.$528
  • AstraZeneca$412
  • Bayer$345
  • Amgen$325
  • Calliditas Therapeutics US Inc.$176
  • plus $667 from 16 others

What the payments were for

  • Food & beverage$2,99999%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,035 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$70,850
Medicare patients
384
Services billed
770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl55$180,444
FarxigaDapagliflozin Propanediol124$86,937
JardianceEmpagliflozin74$51,411
KerendiaFinerenone45$40,222
VelphoroSucroferric Oxyhydroxide14$37,875
Sevelamer Carbonate59$17,531
JanuviaSitagliptin Phosphate11$6,311
Calcium Acetate36$2,282
Midodrine Hcl12$988
Cinacalcet Hcl24$807
Bumetanide33$803
Metolazone38$784
Losartan Potassium63$656
Allopurinol73$551
Furosemide116$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$412$86,937124 claims
Boehringer IngelheimJardiance$53$51,41174 claims
BayerKerendia$345$40,22245 claims
Fresenius USA Marketing, Inc.Velphoro$528$37,87514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.

Other family in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →